Dassault Systemes in talks to buy drug trial software firm ArisGlobal for $2 billion

Dassault Systemes, the French software giant, is reportedly in negotiations to acquire ArisGlobal, a company specializing in drug-trial software. The potential deal is valued at around $2 billion and would significantly bolster Dassault's footprint in the life sciences software market.

This move would mark Dassault's second-largest acquisition, following its substantial $5.8 billion takeover of clinical trial software group Medidata Solutions in 2019. The company, which provides software solutions to various industries including automotive and aerospace, has been increasingly focusing on augmented AI and data centers to drive growth amidst a slowdown in the global auto sector.

While the talks are progressing, the Financial Times, citing sources familiar with the matter, cautioned that a transaction is not guaranteed and negotiations could still collapse. Representatives for Dassault Systemes, ArisGlobal, and Nordic Capital, ArisGlobal's current owner, have not yet commented on the reported discussions.